Cancer Research SA

Running trials

• Recruiting

  A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

  NCT07524855· Phase 1· Source

• Recruiting

  A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

  NCT07195916· Phase 1· Source

• Recruiting

  A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07111520· Phase 1/2· Source

• Recruiting

  A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

  NCT07147348· Phase 1/2· Source

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· Source

• Active, not recruiting

  A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

  NCT06830850· Phase 1· Source

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· Source

• Recruiting

  A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

  NCT06827236· Phase 1/2· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· Phase 3· Source

• Recruiting

  Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

  NCT06750185· Phase 1/2· Source

• Recruiting

  A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

  NCT06533332· Phase 1· Source

• Active, not recruiting

  M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

  NCT06421935· Phase 1· Source

• Recruiting

  A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  NCT06400472· Phase 1· Source

• Active, not recruiting

  Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

  NCT06225596· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  NCT06065748· Phase 3· Source

• Active, not recruiting

  Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

  NCT05909397· Phase 3· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Source

• Active, not recruiting

  A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

  NCT05388669· Phase 3· Source

• Recruiting

  Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

  NCT05142189· Phase 1· Source

• Active, not recruiting

  THIO Sequenced With Cemiplimab in Advanced NSCLC

  NCT05208944· Phase 2· Source

• Active, not recruiting

  A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

  NCT05307705· Phase 1· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Source

• Active, not recruiting

  Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

  NCT04956640· Phase 1/2· Source

• Active, not recruiting

  A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

  NCT04534205· Phase 2/3· Source

• Active, not recruiting

  Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

  NCT04140526· Phase 1/2· Source

• Active, not recruiting

  A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

  NCT04188548· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer5 recruiting
• Endometrial cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Ovarian cancer2 recruiting
• Pancreatic cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Gastric and esophageal cancer1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

  NCT05858736· Phase 1· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

  NCT04958785· Phase 2· Source